These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 26939026)
1. Cardiovascular risk reduction: the future of cholesterol lowering drugs. Bou Malham S; Goldberg AC Curr Opin Pharmacol; 2016 Apr; 27():62-9. PubMed ID: 26939026 [TBL] [Abstract][Full Text] [Related]
2. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
3. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. Agabiti Rosei E; Salvetti M High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901 [TBL] [Abstract][Full Text] [Related]
4. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events. Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008 [TBL] [Abstract][Full Text] [Related]
5. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
9. New Drugs for Lowering LDL-Cholesterol. Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561 [TBL] [Abstract][Full Text] [Related]
10. LDL-Cholesterol: Standards of Treatment 2016: A German Perspective. März W; Scharnagl H; Gouni-Berthold I; Silbernagel G; Dressel A; Grammer TB; Landmesser U; Dieplinger H; Windler E; Laufs U Am J Cardiovasc Drugs; 2016 Oct; 16(5):323-36. PubMed ID: 27430233 [TBL] [Abstract][Full Text] [Related]
11. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy? Cervelli N; Tocci G; Ferri C High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812 [No Abstract] [Full Text] [Related]
12. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value. Tice JA; Kazi DS; Pearson SD JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572 [No Abstract] [Full Text] [Related]
17. PCSK9 antibodies: A new class of lipid-lowering drugs. Gouni-Berthold I Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300 [TBL] [Abstract][Full Text] [Related]
18. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Zheng-Lin B; Ortiz A Drugs; 2018 Feb; 78(2):215-229. PubMed ID: 29299849 [TBL] [Abstract][Full Text] [Related]
19. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
20. [Up to date lipid lowering treatment]. Paragh G; Karádi I Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]